Back to Search Start Over

Long-Term Results after Intraocular Surgery in Treated Retinoblastoma Eyes.

Authors :
Rating P
Bornfeld N
Schlüter S
Westekemper H
Kiefer T
Stuschke M
Göricke S
Ketteler P
Ting S
Metz KA
Bechrakis NE
Biewald E
Source :
Ocular oncology and pathology [Ocul Oncol Pathol] 2022 Nov; Vol. 8 (3), pp. 161-167. Date of Electronic Publication: 2022 Apr 20.
Publication Year :
2022

Abstract

Introduction: The aim of the study was to analyze the results of intraocular surgery in treated retinoblastoma eyes and to assess the long-term results with a priority on local recurrences, secondary enucleation, and metastases. Methods: Retrospective noncomparative case series. Results: From March 1964 to January 2020, 42 eyes of 40 retinoblastoma patients underwent intraocular surgery. Time interval between the last therapy and surgery was 9.5 years (mean: 114 months; median: 54.5 months). 31 eyes were treated for radiogenic cataract formation with a gain in visual acuity of 61.3%. One child developed an upper eyelid metastasis, 3 showed second primary malignancies (SPM), one a late recurrence, and 2 eyes were enucleated. Retinal surgery was performed in 17 eyes; 6 eyes were done as a combined procedure. Indications were radiogenic complications in the sense of a vitreous hemorrhage in 11 eyes and a rhegmatogenous retinal detachment in 6 eyes. 41.2% of the treated eyes had a postoperative gain in visual acuity, whereas 9.5% of the eyes could not be preserved in the long term. Regarding systemic involvement 2 patients developed late recurrences and one a SPM. Conclusion: Surgical therapy in treated retinoblastoma is necessary in isolated cases. In our series, cataract surgery was a safe procedure with a good option of a significant increase in visual acuity. As expected, vitreoretinal treated eyes showed a limited gain in visual acuity, a higher risk of late recurrences, and a lower globe retention rate. Therefore, a careful indication and individual risk-benefit analysis are mandatory.<br /> (© 2022 S. Karger AG, Basel.)

Details

Language :
English
ISSN :
2296-4681
Volume :
8
Issue :
3
Database :
MEDLINE
Journal :
Ocular oncology and pathology
Publication Type :
Academic Journal
Accession number :
36938377
Full Text :
https://doi.org/10.1159/000524610